Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 1,664 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 1,664 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $145.55, for a total value of $242,195.20. Following the completion of the transaction, the chief executive officer now directly owns 198,365 shares of the company's stock, valued at $28,872,025.75. The trade was a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, March 31st, Steven Leonard Chapman sold 9,563 shares of Natera stock. The shares were sold at an average price of $138.41, for a total transaction of $1,323,614.83.
• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The stock was sold at an average price of $146.03, for a total value of $978,693.06.
• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41.

Natera Stock Down 0.4 %

Natera stock traded down $0.69 during trading on Friday, reaching $153.79. The stock had a trading volume of 806,949 shares, compared to its average volume of 1,383,185. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 52-week low of $90.88 and a 52-week high of $183.00. The stock has a market cap of $20.79 billion, a PE ratio of -87.38 and a beta of 1.80. The business has a 50 day moving average price of $147.95 and a 200 day moving average price of $153.71.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NTRA. BTIG Research restated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Robert W. Baird lifted their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Piper Sandler raised their price objective on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. Guggenheim boosted their target price on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday, January 17th. Finally, Barclays lowered their price objective on Natera from $200.00 to $160.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and a consensus price target of $175.76.

Hedge Funds Weigh In On Natera

Several hedge funds have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB purchased a new stake in Natera in the third quarter valued at $385,000. Everence Capital Management Inc. acquired a new stake in Natera during the 4th quarter worth approximately $573,000. Smartleaf Asset Management LLC grew its stake in shares of Natera by 50.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock valued at $104,000 after purchasing an additional 220 shares during the last quarter. SeaBridge Investment Advisors LLC purchased a new stake in shares of Natera during the fourth quarter worth approximately $2,894,000. Finally, SYM FINANCIAL Corp acquired a new stake in shares of Natera during the fourth quarter worth $256,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.